Medtronic Reports Strong Q3 FY26 Results, Exceeding Revenue and EPS Guidance with Key Product Launches

summarizeSummary

Medtronic plc announced strong third quarter fiscal year 2026 financial results, exceeding revenue and non-GAAP EPS guidance, driven by robust growth in key portfolios and significant product approvals.

check_boxKey Events

• Exceeded Q3 FY26 Financial Guidance

  Medtronic reported Q3 revenue of $9.017 billion, an 8.7% reported increase and 6.0% organic growth, exceeding guidance by 50 basis points. Non-GAAP diluted EPS of $1.36 was three cents ahead of the guidance mid-point.

• Strong Growth in Cardiovascular Portfolio

  The Cardiovascular Portfolio revenue increased 10.6% organically, with Cardiac Ablation Solutions growing 80% year-over-year, including 137% in the U.S., driven by its pulsed field ablation portfolio.

• Key Product Approvals and Launches

  The company secured CE Mark for Sphere-360™ and initiated its U.S. pivotal trial, along with U.S. FDA clearances for the Hugo™ robotic-assisted surgery system and Stealth AXiS™ Surgical System for spinal procedures.

• Diabetes Business Shows Robust International Growth

  Diabetes revenue increased 8.3% organically, primarily fueled by double-digit strength in international markets.

auto_awesomeAnalysis

Medtronic plc delivered a strong third quarter, surpassing both revenue and non-GAAP EPS guidance. The company's 6.0% organic revenue growth, coupled with an 8.7% reported increase to $9.017 billion, demonstrates robust operational performance. Key drivers include exceptional growth in the Cardiovascular portfolio, particularly Cardiac Ablation Solutions, which surged 80% year-over-year. Significant regulatory milestones, such as U.S. FDA clearance for the Hugo™ robotic-assisted surgery system and Stealth AXiS™ Surgical System, alongside a CE Mark for Sphere-360™, highlight a strong innovation pipeline. The reaffirmation of full-year FY26 organic revenue and non-GAAP EPS guidance, despite the strong Q3 beat, suggests management's confidence in sustained performance. This filing indicates positive momentum for Medtronic, driven by strategic investments in high-growth opportunities and successful product commercialization.